Hannah Clarke

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.

The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan and enzalutamide led to an improvement in prostate-specific antigen progression-free survival vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer.

The use of talazoparib plus enzalutamide was manageable with dose modifications or standard supportive care treatment in patients with metastatic castration-resistant prostate cancer.